Perspective Therapeutics CATX
NYSE CATX
$2.98 -0.14 (-4.49%)
As of: Sep 9, 2026 · 3:59 PM EDT

Perspective Therapeutics (CATX) Net Income (2010 - 2026)

Perspective Therapeutics' (CATX) quarterly Net Income came in at -$26.8 million in Q2 2026, down 24.67% year-over-year from -$35.6 million in Q2 2025, and up 6.74% quarter-over-quarter from -$28.7 million in Q1 2026.

Analysis

Perspective Therapeutics (CATX) Net Income (2010 - 2026) Analysis & Trends

Perspective Therapeutics has disclosed Net Income across 17 years of filings, most recently posting -$26.8 million for Q2 2026.

  • In Q2 2026, Net Income fell 24.67% year-over-year to -$26.8 million; the TTM figure through Jun 2026 stood at -$119.8 million (down 22.21% YoY), while the FY2025 annual figure was -$103.9 million, down 26.22% from the prior year.
  • Net Income came in at -$26.8 million for Q2 2026 at Perspective Therapeutics, up from -$28.7 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$1.3 million in Q1 2022 to a low of -$43.2 million in Q4 2024.
  • Average Net Income over 5 years is -$17.3 million, with a median of -$13.9 million recorded in 2023.
  • Year-over-year, Net Income slumped 568.7% in 2024 and gained 11.41% in 2025.
  • Over 5 years, Net Income stood at -$8.5 million in 2022, then sank by 171.57% to -$23.2 million in 2023, then plunged by 86.18% to -$43.2 million in 2024, then grew by 11.41% to -$38.3 million in 2025, then surged by 30.03% to -$26.8 million in 2026.
  • Per Business Quant data, the three most recent Net Income figures were -$26.8 million in Q2 2026, -$28.7 million in Q1 2026, and -$38.3 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 2.38 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn -10.50 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 1.10 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 1.30 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn 601.00 Mn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn -782.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 164.49 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 97.50 Mn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -290.61 Mn
10 Perspective Therapeutics 361.95 Mn 361.95 Mn - -26.79 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -26.79 Mn
Mar 31, 2026 -28.72 Mn
Dec 31, 2025 -38.28 Mn
Sep 30, 2025 -25.97 Mn
Jun 30, 2025 -21.49 Mn
Mar 31, 2025 -18.18 Mn
Dec 31, 2024 -43.22 Mn
Sep 30, 2024 -15.12 Mn
Jun 30, 2024 -11.70 Mn
Mar 31, 2024 -12.28 Mn
Dec 31, 2023 -23.21 Mn
Sep 30, 2023 -11.14 Mn
Jun 30, 2023 -12.73 Mn
Mar 31, 2023 -1.84 Mn
Dec 31, 2022 -8.55 Mn
Sep 30, 2022 -7.49 Mn
Jun 30, 2022 -3.43 Mn
Mar 31, 2022 -1.35 Mn
Dec 31, 2021 -1.60 Mn
Sep 30, 2021 -2.24 Mn